Endometrial cancer differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
| Line 39: | Line 39: | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Imaging</small> | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Imaging</small> | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small> | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Menorrhagia</small> | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small> | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small> | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Post Menstrual</small> | ||
<small>Bleeding</small> | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Pelvic P</small><small>ain</small> | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Other</small> | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Other</small> | ||
<small>symptoms</small> | <small>symptoms</small> | ||
| Line 152: | Line 154: | ||
<small>invasion</small> | <small>invasion</small> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |<small>+</small> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 170: | Line 172: | ||
<small>malignancy</small> | <small>malignancy</small> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |<small>+</small> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 187: | Line 189: | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrial polyp|<small>Endometrial</small>]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrial polyp|<small>Endometrial</small>]] | ||
[[Endometrial polyp|<small>polyp</small>]] | [[Endometrial polyp|<small>polyp</small>]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |<small>+</small> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 208: | Line 210: | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrial hyperplasia|<small>Endometrial</small>]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrial hyperplasia|<small>Endometrial</small>]] | ||
[[Endometrial hyperplasia|<small>hyperplasia</small>]] | [[Endometrial hyperplasia|<small>hyperplasia</small>]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |<small>+</small> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 241: | Line 243: | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Adenomyoma|<small>Uterine</small>]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Adenomyoma|<small>Uterine</small>]] | ||
[[Adenomyoma|<small>adenomyoma</small>]] | [[Adenomyoma|<small>adenomyoma</small>]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |<small>-</small> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 257: | Line 259: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hematometra|<small>Hematometra</small>]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hematometra|<small>Hematometra</small>]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |<small>-</small> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Revision as of 19:43, 29 January 2019
|
Endometrial cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Endometrial cancer differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Endometrial cancer differential diagnosis |
|
Risk calculators and risk factors for Endometrial cancer differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monalisa Dmello, M.B,B.S., M.D. [2]Roukoz A. Karam, M.D.[3]
Overview
In early stages endometrial cancer must be differentiated from diseases that cause abnormal uterine bleeding and endometrial thickening on ultrasound, such as endometrial hyperplasia, endometrial polyp and submucosal uterine leiomyoma. In advanced stages endometrial cancer must be differentiated from uterine sarcoma and uterine lymphoma.
Differentiating Endometrial Cancer From Other Diseases
- In early disease, uterine cancer must be differentiated from other diseases causing endometrial thickening:[1]
- Benign endometrial proliferation
- Endometrial hyperplasia
- Endometrial polyp
- Submucosal uterine leiomyoma
- In advanced disease, uterine cancer must be differentiated from other diseases:[1]
-
- Endometrial stromal sarcoma (ESS)
- Leiomyosarcoma of the uterus
- Malignant mixed Mullerian tumour (MMMT) of the uterus
- Uterine lymphoma: rare
- Primary uterine lymphoma
- Secondary uterine involvement with lymphoma
- Cervical cancer with uterine invasion
- Metastasis to the uterus from a non gynecological malignancy: rare
| Diseases | Clinical manifestations | Para-clinical findings | Pap Smear | Histopathology | Gold standard | Additional findings | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Symptoms | Physical examination | |||||||||||||
| Lab Findings | Imaging | |||||||||||||
| Menorrhagia | Post Menstrual
Bleeding |
Pelvic Pain | Other
symptoms |
Pelvic Mass | Abdominal Distension | Hb | CEA-19 | Ultrasound | MRI | |||||
| Uterine cancer | + | ↓ | ||||||||||||
| Uterine | +/- | ↓ | ||||||||||||
| Uterine | +/- | ↓
or N |
||||||||||||
| Uterine leiomyoma | +/- | ↓
or N |
||||||||||||
| Malignant mixedMullerian
tumour (MMMT) of the uterus |
+/- | ↓ | ||||||||||||
| Cervical cancerwith
uterine invasion |
+ | ↓ | ||||||||||||
| Metastasis to the uterusfrom a non gynaecologcial
malignancy |
+ | ↓ | ||||||||||||
| Endometrial | + | ↓
or N |
||||||||||||
| Endometrial | + | ↓ | ||||||||||||
| Fetus | - | |||||||||||||
| Uterine | - | ↓ | ||||||||||||
| Hematometra | - | ↓ | ||||||||||||
References
- ↑ 1.0 1.1 Hippisley-Cox J, Coupland C (2011). "Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm". BMJ. 344: d8009. doi:10.1136/bmj.d8009. PMC 3251328. PMID 22217630.